| Literature DB >> 23793704 |
Lawrence Mbuagbaw1, Mia L van der Kop, Richard T Lester, Harsha Thirumurthy, Cristian Pop-Eleches, Marek Smieja, Lisa Dolovich, Edward J Mills, Lehana Thabane.
Abstract
INTRODUCTION: Mobile phone text messaging is emerging as an important tool in the care of people living with HIV; however, reports diverge on its efficacy in improving adherence to antiretroviral therapy (ART), and little is known about which patient groups may benefit most from phone-based adherence interventions. We will conduct an individual patient data meta-analysis to investigate the overall and subgroup effects of text messaging in three recently published text-messaging randomised controlled trials. METHODS AND ANALYSIS: Data from two Kenyan and one Cameroonian trial will be verified, reformatted and merged. We will determine pooled effect sizes for text messaging versus standard care for improving adherence to ART using individual patient random-effects meta-analysis. We will test for the interaction effects of age, gender, level of education and duration on ART. Sensitivity analyses will be conducted with regard to thresholds for adherence, methods of handling missing data and fixed-effects meta-analysis. Only anonymised data will be collected from the individual studies. ETHICS AND DISSEMINATION: Ethical approval was obtained for the individual studies. The results of this paper will be disseminated as peer-reviewed publications, at conferences and as part of a doctoral thesis. This individual patient data meta-analysis may provide important insights into the effects of text messaging on ART adherence in different subpopulations, with important implications for programme implementation involving such interventions and future research.Entities:
Keywords: Statistics & Research Methods
Year: 2013 PMID: 23793704 PMCID: PMC3664352 DOI: 10.1136/bmjopen-2013-002954
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of included studies
| Lester | Pop-Eleches | Mbuagbaw | |
|---|---|---|---|
| Design | A multisite two-arm randomised controlled trial | A single site five-arm randomised controlled trial | A single site two-arm randomised controlled trial |
| Inclusion criteria | ≥18-years-old, initiating ART for the first time, and able to access a mobile phone on a near-daily basis and communicate via SMS | ≥18 age who had initiated ART less than 3 months prior to enrolment | ≥21 years who owned mobile phones, could read text messages and had been on ART for at least 1 month |
| Baseline characteristics reported | Gender, age, CD4 count, WHO stage, clinic, viral load, literacy, level of education, monthly income, mobile phone access and residence | Marital status, religion, language, roofing, education, gender and age | Age, gender, education, family awareness of HIV status, presence of OI, BMI, CDC stage, regimen, duration on ART, CD4 count and VAS adherence |
| Sample size | 538 (intervention=273; control=265) | 431 (Short daily message=70; Short weekly message=73; Long daily message=72; Long weekly message=74; Control=139 | 200 (intervention=101; control=99) |
| Interventions | Weekly text message inquiring about status- Participants required to respond in 48 h | Short daily message | Varied weekly motivational text message with response number provided |
| Control | Standard care | Standard care | Standard care |
| Primary outcomes | Self reported adherence (in preceding month), viral load | MEMS adherence | VAS adherence, number of missed doses (in preceding week), PRD |
| Secondary outcomes | Attrition (loss to follow-up, mortality, transfers, withdrawals) | Treatment interruptions | Weight, BMI, opportunistic infections, CD4 count, viral load, QOL, all cause mortality, retention in care |
| Duration of follow-up | 12 months | 48 weeks (12 months) | 6 months |
| Overall findings | Improved adherence and reduced viral load | Improved adherence and reduced treatment interruptions | No improvements in adherence |
ART, antiretroviral therapy; BMI, body mass index; CD4 count, CD4-positive-T-lymphocyte count; CDC, Centres for Disease Control and Prevention; MEMS, Medication Event Monitoring System; OI, opportunistic infection; PRD, pharmacy refill data; QOL, quality of life; SMS, short message service; VAS, visual analogue scale.
Data merging procedures
| Variable | Lester | Pop-Eleches | Mbuagbaw | IPD* Meta-analysis |
|---|---|---|---|---|
| Age | Years | Years | Years | Years |
| Gender | Male/female | Male/female | Male/female | Male/female |
| Level of education | No formal education | None | None | None |
| Lower primary | Completed primary | Primary | Primary | |
| Lower secondary | Completed secondary | Secondary | Secondary or higher | |
| Middle college and University | University | |||
| Duration on ART | Months | Months | Months | Months |
| Intervention | SMS short daily | SMS short daily | ||
| SMS short weekly | SMS short weekly | SMS short weekly | ||
| SMS long daily | SMS long daily | |||
| SMS long weekly | SMS Long weekly | SMS long weekly | ||
| Control | No SMS | No SMS | No SMS | No SMS |
| Adherence | Yes (>95 at 6 & 12 months) | Yes (≥95% from 12 to 48 weeks) | Yes (>95% at 6 months) | Yes (as reported in studies) |
| Final outcome | Lost to follow-up | Lost to follow-up | Lost to follow-up | Lost to follow-up |
| Death | Death | Death | Death | |
| Withdrew | Withdrew | Withdrew | Withdrew | |
| Transferred out | Transferred out | Transferred out | Transferred out |
*Individual patient data.
SMS, short message service.
Figure 1Analysis plan for individual patient data.